公开(公告)号：EP2086973B1

公开(公告)日：2012-01-25

申请号：EP07839356.8

申请日：2007-10-05

申请人： Amgen Inc.,

发明人： ZHANG, Dawei ,  TASKER, Andrew ,  SHAM, Kelvin, K.C. ,  CHAKRABARTI, Partha, Pratim ,  FALSEY, Richard, James ,  HERBERICH, Bradley, J. ,  PETTUS, Liping, H. ,  RZASA, Robert, M.

IPC分类号： C07D471/04

CPC分类号： C07D471/04

摘要： The present invention comprises a new class of compounds useful for the prophylaxis and treatment of protein kinase mediated diseases, including inflammation and related conditions. The compounds have general Formula (I), wherein A, B, R1, R2, R3 and R4 are defined herein. The invention also comprises pharmaceutical compositions including one or more compounds of Formula (I), uses of such compounds and compositions for treatment of P38 map kinase mediated diseases including rheumatoid arthritis, psoriasis and other inflammation disorders, as well as intermediates and processes useful for the preparation of compounds of Formula (I).

公开(公告)号：EP2424859A1

公开(公告)日：2012-03-07

申请号：EP10718364.2

申请日：2010-04-27

申请人： Amgen, Inc

发明人： ANDREWS, Kristin ,  BO, Yunxin, Y. ,  BOOKER, Shon ,  CEE, Victor, J. ,  D'ANGELO, Noel ,  HERBERICH, Bradley, J. ,  HONG, Fang-Tsao ,  JACKSON, Claire, L., M. ,  LANMAN, Brian, A. ,  LIAO, Hongyu ,  LIU, Longbin ,  NISHIMURA, Nobuko ,  NORMAN, Mark, H. ,  PETTUS, Liping, H. ,  REED, Anthony, B. ,  SMITH, Adrian, L. ,  TADESSE, Seifu ,  TAMAYO, Nuria, A. ,  WU, Bin ,  WURZ, Ryan ,  YANG, Kevin

IPC分类号： C07D401/14 ,  C07D473/00 ,  A61K31/52 ,  A61P35/00

CPC分类号： C07D473/00 ,  C07D401/14 ,  C07D405/14 ,  C07D413/14 ,  C07D417/14

摘要： The present invention relates to compounds of Formula I, or a pharmaceutically acceptable salt thereof; methods of treating diseases or conditions, such as cancer, using the compounds; and pharmaceutical compositions containing the compounds, wherein the variables are as defined herein.

公开(公告)号：EP2424859B1

公开(公告)日：2015-04-08

申请号：EP10718364.2

申请日：2010-04-27

申请人： Amgen, Inc

发明人： ANDREWS, Kristin ,  BO, Yunxin, Y. ,  BOOKER, Shon ,  CEE, Victor, J. ,  D'ANGELO, Noel ,  HERBERICH, Bradley, J. ,  HONG, Fang-Tsao ,  JACKSON, Claire, L., M. ,  LANMAN, Brian, A. ,  LIAO, Hongyu ,  LIU, Longbin ,  NISHIMURA, Nobuko ,  NORMAN, Mark, H. ,  PETTUS, Liping, H. ,  REED, Anthony, B. ,  SMITH, Adrian, L. ,  TADESSE, Seifu ,  TAMAYO, Nuria, A. ,  WU, Bin ,  WURZ, Ryan ,  YANG, Kevin

IPC分类号： C07D401/14 ,  C07D473/00 ,  A61K31/52 ,  A61P35/00

CPC分类号： C07D473/00 ,  C07D401/14 ,  C07D405/14 ,  C07D413/14 ,  C07D417/14

公开(公告)号：EP2688886A1

公开(公告)日：2014-01-29

申请号：EP12719496.7

申请日：2012-03-21

申请人： Amgen Inc.

发明人： WANG, Hui-Ling ,  CEE, Victor, J. ,  HERBERICH, Bradley, J. ,  JACKSON, Claire, L., M. ,  LANMAN, Brian, Alan ,  NIXEY, Thomas ,  PETTUS, Liping, H. ,  REED, Anthony, B. ,  WU, Bin ,  WURZ, Ryan ,  TASKER, Andrew

IPC分类号： C07D413/14 ,  C07D417/14 ,  C07D417/04 ,  C07D487/04 ,  A61K31/496 ,  A61K31/4439 ,  A61K31/4745 ,  A61K31/433 ,  A61P35/00

CPC分类号： C07D413/14 ,  C07D417/04 ,  C07D417/14 ,  C07D471/04 ,  C07D487/04

摘要： The invention relates to bicyclic compounds of formulas I and Ia, and salts thereof. In some embodiments, the invention relates to inhibitors or modulators of Pim-1 and/or Pim-2, and/or Pim-3 protein kinase activity or enzyme function. In still further embodiments, the invention relates to pharmaceutical compositions comprising compounds disclosed herein, and their use in the prevention and treatment of Pim kinase related conditions and diseases, preferably cancer.

公开(公告)号：EP2086973A2

公开(公告)日：2009-08-12

申请号：EP07839356.8

申请日：2007-10-05

申请人： Amgen Inc.,

发明人： ZHANG, Dawei ,  TASKER, Andrew ,  SHAM, Kelvin, K.C. ,  CHAKRABARTI, Partha, Pratim ,  FALSEY, Richard, James ,  HERBERICH, Bradley, J. ,  PETTUS, Liping, H. ,  RZASA, Robert, M.

IPC分类号： C07D471/04

CPC分类号： C07D471/04

摘要： The present invention comprises a new class of compounds useful for the prophylaxis and treatment of protein kinase mediated diseases, including inflammation and related conditions. The compounds have general Formula (I), wherein A, B, R1, R2, R3 and R4 are defined herein. The invention also comprises pharmaceutical compositions including one or more compounds of Formula (I), uses of such compounds and compositions for treatment of P38 map kinase mediated diseases including rheumatoid arthritis, psoriasis and other inflammation disorders, as well as intermediates and processes useful for the preparation of compounds of Formula (I).

公开(公告)号：EP1727821A1

公开(公告)日：2006-12-06

申请号：EP05705583.2

申请日：2005-01-12

申请人： Amgen Inc.

发明人： CAO, Guo-Qiang ,  CHEN, Jian, J. ,  DOMINGUEZ, Celia ,  REED, Anthony ,  SHAM, Kelvin, K., C. ,  THAMAN, Maya, C. ,  ZHANG, Dawei ,  HERBERICH, Bradley, J.

IPC分类号： C07D487/08 ,  A61K31/4995 ,  A61P19/02

CPC分类号： C07D487/06 ,  C07D213/56 ,  C07D239/95 ,  C07D401/04 ,  C07D401/14 ,  C07D417/14

摘要： The present invention relates to therapeutic diazobicyclo pyridines and their use in the treatment of arthritis, rheumatoid arthritis, psoriatic arthritis or osteoarthritis, organ transplant, acute transplant or heterograft and homograft rejection, ischemic and reperfusion injury, transplantation tolerance induction, multiple sclerosis, inflammatory bowel disease, ulcerative colitis, Crohn's disease, lupus, graft vs. host diseases, T -cell mediated hypersensitivity diseases, contact hypersensitivity, delayed-type hypersensitivity, gluten-sensitive enteropathy, Type 1 diabetes, psoriasis, contact dermatitis, Hashimoto's thyroiditis, Sjogren's syndrome, autoimmune hyperthyroidism,Graves' Disease, Addison's disease, autoimmune polyglandular disease, autoimmune alopecia, pernicious anemia, vitiligo, autoimmune hypopituatarism, Guillain-Barre syndrome, autoimmune diseases, glomerulonephritis, serum sickness, uticaria, respiratory allergies, asthma, hayfever, allergic rhinitis, skin allergies, scleracielma, mycosis fungoides, acute inflammatory responses, acute respiratory distress syndrome, dermatomyositis, alopecia areata, chronic actinic dermatitis, eczema, Behcet's disease, Pustulosis palmoplanteris, Pyoderma gangrenum, Sezary's syndrome, atopic dermatitis, systemic schlerosis, morphea, Type II diabetes and cancers where PKC theta or other PKC-family kinases are activated, overexpressed or facilitate tumor growth or survival of tumor cells, T cell leukemia, thymoma, T and B cell lymphoma, colon carcinoma, breast carcinoma and lung carcinoma or provides resistance to chemotherapeutic drugs.